Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer

Human cytochrome P450 2B6 (CYP2B6) metabolizes the prodrug cyclophosphamide (CPA) to produce phosphoramide mustard that cross-links DNA leading to cell death. We have constructed a novel retroviral vector encoding CYP2B6 (designated “MetXia-P450”) and used it to transduce the human tumor cell lines HT29 and T47D. MetXia-P450 transduction sensitised these cells to the cytotoxic effects of the prodrug CPA. Results from in vitro experiments demonstrated adverse effects on the clonogenic survival of cyclophosphamide-treated cells transduced with MetXia-P450. Cytotoxic activity accompanied by bystander effect was particularly evident in 3-D multicellular spheroid models suggesting that this in vitro system may be a more appropriate model for assessing the efficacy of gene directed-enzyme prodrug therapy (GDEPT). We have applied this approach in a clinically relevant gene therapy protocol on established subcutaneous tumor xenografts. These studies show for the first time the efficacy of a P450-based GDEPT strategy mediated by a direct retroviral gene transfer in vivo. Cancer Gene Therapy (2001) 8, 473–482

[1]  Y Takeuchi,et al.  High-titer packaging cells producing recombinant retroviruses resistant to human serum , 1995, Journal of virology.

[2]  J. Miller,et al.  Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system , 1987, Molecular and cellular biology.

[3]  R. Chung,et al.  An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy , 1998, Nature Biotechnology.

[4]  D. Meruelo,et al.  Cell‐specific targeting of a thymidine kinase/ganciclovir gene therapy system using a recombinant sindbis virus vector , 1999, International journal of cancer.

[5]  M. Löhr,et al.  Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy. , 1998, Advances in experimental medicine and biology.

[6]  X. Breakefield,et al.  Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. , 1994, Human gene therapy.

[7]  H. Chong,et al.  Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells. , 1997, Biochemical Society transactions.

[8]  D. Waxman,et al.  Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. , 1995, Cancer research.

[9]  Erich A. Nigg,et al.  Nucleocytoplasmic transport: signals, mechanisms and regulation , 1997, Nature.

[10]  H. Chong,et al.  Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity. , 1996, Human gene therapy.

[11]  J. Wilson,et al.  The effect of promoter strength in adenoviral vectors containing herpes simplex virus thymidine kinase on cancer gene therapy in vitro and in vivo. , 1997, Cancer gene therapy.

[12]  D. Waxman,et al.  Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. , 1996, Cancer research.

[13]  P. Wen,et al.  Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. , 1996, Gene therapy.

[14]  Connors Ta.  The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. , 1995 .

[15]  X. Breakefield,et al.  Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  Miller Ad,et al.  Improved Retroviral Vectors for Gene Transfer and Expression , 1989 .

[17]  A. Kingsman,et al.  A transient three-plasmid expression system for the production of high titer retroviral vectors. , 1995, Nucleic acids research.

[18]  D. Kerr,et al.  Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. , 1997, Cancer gene therapy.

[19]  D. Waxman,et al.  Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. , 1998, Cancer research.

[20]  X. Breakefield,et al.  Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. , 1999, Cancer research.

[21]  R. Sutherland.  Cell and environment interactions in tumor microregions: the multicell spheroid model. , 1988, Science.

[22]  W. Denny,et al.  Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. , 1997, Journal of medicinal chemistry.

[23]  B. Nebe,et al.  Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450 , 1998, Gene Therapy.